Cargando…

Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen

We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch repair (dMMR), and determine the optimum time to start chemotherapy after surgery. Data of 306 colon cancer patients with dMMR who received radical surgery w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhan, Yixiang, Ni, Kemin, Liu, Zhaoce, xin, Ran, Han, Qiurong, Ping, Hangyu, Liu, Yaohong, Zhao, Xuanzhu, Wang, Wanting, Yan, Suying, Sun, Jing, Zhang, Qinghuai, Wang, Guihua, Zhang, Zili, Zhang, Xipeng, Hu, Xia, Li, Guoxun, Zhang, Chunze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238399/
https://www.ncbi.nlm.nih.gov/pubmed/37268749
http://dx.doi.org/10.1038/s41598-023-33153-8
_version_ 1785053284176756736
author Zhan, Yixiang
Ni, Kemin
Liu, Zhaoce
xin, Ran
Han, Qiurong
Ping, Hangyu
Liu, Yaohong
Zhao, Xuanzhu
Wang, Wanting
Yan, Suying
Sun, Jing
Zhang, Qinghuai
Wang, Guihua
Zhang, Zili
Zhang, Xipeng
Hu, Xia
Li, Guoxun
Zhang, Chunze
author_facet Zhan, Yixiang
Ni, Kemin
Liu, Zhaoce
xin, Ran
Han, Qiurong
Ping, Hangyu
Liu, Yaohong
Zhao, Xuanzhu
Wang, Wanting
Yan, Suying
Sun, Jing
Zhang, Qinghuai
Wang, Guihua
Zhang, Zili
Zhang, Xipeng
Hu, Xia
Li, Guoxun
Zhang, Chunze
author_sort Zhan, Yixiang
collection PubMed
description We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch repair (dMMR), and determine the optimum time to start chemotherapy after surgery. Data of 306 colon cancer patients with dMMR who received radical surgery were collected from three Chinese centers between August 2012 and January 2018. Overall survival (OS) was assessed with the Kaplan–Meier method and log-rank. Cox regression analysis were used to assess influencing prognosis factors. The median follow-up time for all patients was 45.0 months (range, 1.0–100). There was a nonsignificant OS benefit from chemotherapy for patients with stage I and stage II disease, including high-risk stage II disease (log-rank p: 0.386, 0.779, 0.921), and a significant OS benefit for patients with stage III and stage IV disease for receiving post-operation chemotherapy (log-rank p = 0.002, 0.019). Stage III patients benefitted from chemotherapy regimens that contained oxaliplatin (log-rank p = 0.004), and Starting chemotherapy with oxaliplatin treatment earlier resulted in better outcomes (95% CI 0.013–0.857; p = 0.035). Chemotherapy regimens containing oxaliplatin can prolong the survival time of stage III and IV dMMR colon cancer patients. This beneficial manifestation was more pronounced after starting chemotherapy treatment early post operation. High risk stage II dMMR colon patients including T(4)N(0)M(0) cannot benefit from chemotherapy.
format Online
Article
Text
id pubmed-10238399
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102383992023-06-04 Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen Zhan, Yixiang Ni, Kemin Liu, Zhaoce xin, Ran Han, Qiurong Ping, Hangyu Liu, Yaohong Zhao, Xuanzhu Wang, Wanting Yan, Suying Sun, Jing Zhang, Qinghuai Wang, Guihua Zhang, Zili Zhang, Xipeng Hu, Xia Li, Guoxun Zhang, Chunze Sci Rep Article We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch repair (dMMR), and determine the optimum time to start chemotherapy after surgery. Data of 306 colon cancer patients with dMMR who received radical surgery were collected from three Chinese centers between August 2012 and January 2018. Overall survival (OS) was assessed with the Kaplan–Meier method and log-rank. Cox regression analysis were used to assess influencing prognosis factors. The median follow-up time for all patients was 45.0 months (range, 1.0–100). There was a nonsignificant OS benefit from chemotherapy for patients with stage I and stage II disease, including high-risk stage II disease (log-rank p: 0.386, 0.779, 0.921), and a significant OS benefit for patients with stage III and stage IV disease for receiving post-operation chemotherapy (log-rank p = 0.002, 0.019). Stage III patients benefitted from chemotherapy regimens that contained oxaliplatin (log-rank p = 0.004), and Starting chemotherapy with oxaliplatin treatment earlier resulted in better outcomes (95% CI 0.013–0.857; p = 0.035). Chemotherapy regimens containing oxaliplatin can prolong the survival time of stage III and IV dMMR colon cancer patients. This beneficial manifestation was more pronounced after starting chemotherapy treatment early post operation. High risk stage II dMMR colon patients including T(4)N(0)M(0) cannot benefit from chemotherapy. Nature Publishing Group UK 2023-06-02 /pmc/articles/PMC10238399/ /pubmed/37268749 http://dx.doi.org/10.1038/s41598-023-33153-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhan, Yixiang
Ni, Kemin
Liu, Zhaoce
xin, Ran
Han, Qiurong
Ping, Hangyu
Liu, Yaohong
Zhao, Xuanzhu
Wang, Wanting
Yan, Suying
Sun, Jing
Zhang, Qinghuai
Wang, Guihua
Zhang, Zili
Zhang, Xipeng
Hu, Xia
Li, Guoxun
Zhang, Chunze
Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
title Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
title_full Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
title_fullStr Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
title_full_unstemmed Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
title_short Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
title_sort stage iii deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238399/
https://www.ncbi.nlm.nih.gov/pubmed/37268749
http://dx.doi.org/10.1038/s41598-023-33153-8
work_keys_str_mv AT zhanyixiang stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT nikemin stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT liuzhaoce stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT xinran stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT hanqiurong stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT pinghangyu stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT liuyaohong stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT zhaoxuanzhu stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT wangwanting stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT yansuying stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT sunjing stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT zhangqinghuai stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT wangguihua stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT zhangzili stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT zhangxipeng stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT huxia stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT liguoxun stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen
AT zhangchunze stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen